Compare USAS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | NBTX |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | Canada | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2004 | 2018 |
| Metric | USAS | NBTX |
|---|---|---|
| Price | $4.50 | $32.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.50 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 3.5M | 114.2K |
| Earning Date | 05-11-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $174.68 | $58.17 |
| Revenue Next Year | $53.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.48 | $14.78 |
| 52 Week High | $10.50 | $57.14 |
| Indicator | USAS | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.64 | 38.64 |
| Support Level | $3.57 | $32.40 |
| Resistance Level | $6.35 | $34.66 |
| Average True Range (ATR) | 0.25 | 1.85 |
| MACD | -0.07 | -0.29 |
| Stochastic Oscillator | 2.98 | 22.51 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.